These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 10610285)
1. NE 100. Drugs R D; 1999 Jul; 2(1):55-6. PubMed ID: 10610285 [No Abstract] [Full Text] [Related]
2. Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-dipropyl-4-methoxy-3-(2-phenylethoxy)phenylethylamine to discover sigma(1) ligands. Nakazato A; Kumagai T; Ohta K; Chaki S; Okuyama S; Tomisawa K J Med Chem; 1999 Sep; 42(19):3965-70. PubMed ID: 10508444 [TBL] [Abstract][Full Text] [Related]
10. Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors. Hiramatsu M; Hoshino T Brain Res; 2005 Sep; 1057(1-2):72-80. PubMed ID: 16125682 [TBL] [Abstract][Full Text] [Related]
11. A sigma-1 receptor antagonist (NE-100) prevents tunicamycin-induced cell death via GRP78 induction in hippocampal cells. Ono Y; Tanaka H; Tsuruma K; Shimazawa M; Hara H Biochem Biophys Res Commun; 2013 May; 434(4):904-9. PubMed ID: 23618865 [TBL] [Abstract][Full Text] [Related]
12. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Bermack JE; Debonnel G Synapse; 2005 Jan; 55(1):37-44. PubMed ID: 15499608 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice. Hiramatsu M; Hoshino T; Kanematsu K Behav Brain Res; 2005 May; 160(2):374-81. PubMed ID: 15863234 [TBL] [Abstract][Full Text] [Related]
14. Differences in the allosteric modulation by phenytoin of the binding properties of the sigma1 ligands [3H](+)-pentazocine and [3H]NE-100. Cobos EJ; Lucena G; Baeyens JM; Del Pozo E Synapse; 2006 Mar; 59(3):152-61. PubMed ID: 16342057 [TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Lockwood JT; Remington G Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007 [TBL] [Abstract][Full Text] [Related]
19. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Lieberman JA Br J Psychiatry Suppl; 1993 Dec; (22):7-18. PubMed ID: 7906527 [TBL] [Abstract][Full Text] [Related]